RxDoctor Payments Data

Muge Kesen, MD

Retina Specialist · Mc Lean, VANPI 1770676017

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $19,160 of the $29,822 with a category attached, or 64.2%. 23 manufacturers reported payments, led by Genentech USA, Inc. at 57.1% of the total. Among retina specialist clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$29,822in general payments, 2019–2025

Across 69 payments — averaging $432.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$17K
  • AbbVie$6K
  • Regeneron$4K
  • Mallinckrodt Hospital Products Inc.$477
  • Genentech, Inc.$399
  • Alcon$245
  • plus $2K from 17 others

What the payments were for

  • Consulting fees$19,16064%
  • Speaking & faculty fees$4,75016%
  • Travel & lodging$1,8326%
  • Food & beverage$3,90413%
  • Education$850%
  • Entertainment$910%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,822 in reported general payments places this provider in the 90th percentile of 41 retina specialist providers in Virginia.

See all retina specialist providers in Virginia

Medicare billing

Part B allowed, 2024
$356,067
Medicare patients
199
Services billed
3,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium18$9,323
Bromfenac Sodium37$5,086
SimbrinzaBrinzolamide/Brimonidine Tart15$2,700
Prednisolone Acetate53$2,460
Ketorolac Tromethamine71$2,029
Difluprednate20$1,709
Dorzolamide Hcl12$177
ErythromycinErythromycin Base15$156
Timolol Maleate13$150
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat11$135

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$147$9,32318 claims
AlconSimbrinza$245$2,70015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 retina specialist providers in Virginia.

Other retina specialist in Mc Lean

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →